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We have previously described a 4-guanidino-Neu5Ac2en (zanamivir)-resistant neuraminidase (NA) variant G70C4-G, with
an active site mutation Glu 119 to Gly. This variant has been found to also harbor a hemagglutinin (HA) mutation in the
receptor binding site, Ser 186 to Phe. Examination of early passages of the G70C4-G virus revealed that this HA mutation
had arisen by the first passage. From a subsequent passage two transient variants were isolated which had each acquired
a different second HA mutation, Ser 165 to Asn and Lys 222 to Thr. Both were highly drug resistant and drug dependent and
their ability to adsorb to and penetrate cells was decreased. Comparison of drug sensitivities between the variant, with the
additional HA mutation at Ser 165, and viruses with either mutation alone revealed that these two HA mutations acted
synergistically to increase resistance. To determine the contribution to resistance of each of the NA and HA mutations in
G70C4-G, the NA mutation was separated from the HA mutation by reassorting. The NA mutation and the HA mutation each
conferred low-level resistance to zanamivir, while the two mutations interacted synergistically in the double mutant to give
higher resistance in vitro. Infectivity was not adversely affected in the double mutant and while there was a small decrease
in sensitivity to zanamivir in the mouse model, there was no detectable resistance to zanamivir in the ferret model. © 1998
Academic Press
INTRODUCTION
Influenza viruses have two surface glycoproteins, the
hemagglutinin (HA) and neuraminidase (NA). The HA
facilitates virus entry into the cell via its receptor, glyco-
conjugates with sialic acid as the terminal sugar
(Gottschalk, 1959). Viral NA removes terminal sialic acids
from glycoproteins, on both cell receptors and viral HA
and NA, thereby allowing the release of progeny virus
from infected cells (Seto and Rott, 1966; Palese et al.,
1974; Palese and Compans, 1976).
Determination of the crystal structure of influenza virus
NA complexed with sialic acid (Varghese et al., 1992) led
to the rational design of specific inhibitors (von Itzstein et
al., 1993), 4-guanidino-Neu5Ac2en (zanamivir) and 4-ami-
no-Neu5Ac2en. Zanamivir is a potent inhibitor of influ-
enza virus replication in vitro (Woods et al., 1993; Thomas
et al., 1994) and in vivo (Ryan et al., 1994, 1995). Experi-
mental human trials have demonstrated its safety and
efficacy (Hayden et al., 1996).
Resistant variants to zanamivir have been generated
in vitro, with mutations found both in the active site of the
NA and/or in the region of the receptor binding pocket of
the HA (Blick et al., 1995; Staschke et al., 1995; McKimm-
Breschkin et al., 1996a, 1998; Gubareva et al., 1996,
1997). These HA mutations were proposed to affect its
affinity or specificity, resulting in a weakly binding HA
and allowing for release of progeny virions from infected
cells with less dependence on the NA (McKimm-Bresch-
kin et al., 1996a).
We have previously described an NA variant, G70C4-G,
with the active site mutation Glu 119 to Gly (Blick et al.,
1995). This variant showed decreased sensitivity to zana-
mivir in enzyme assays, but not to 4-amino-Neu5Ac2en.
Surprisingly this variant demonstrated cross-resistance to
both zanamivir and 4-amino-Neu5Ac2en in cell culture. It
was subsequently found also to have an HA mutation. To
determine the contribution to resistance of each mutation,
variants with either the HA or NA mutation were obtained.
The interaction of the two mutations in combination was
assessed by comparing the drug sensitivity of the G70C4-G
variant to the sensitivity of the single HA or NA variants.
Evolution of this double mutant was further studied by
selection and characterization of progeny at each passage.
The mouse and ferret models were used to determine the
in vivo infectivity of G70C4-G and to measure its sensitivity
to zanamivir.
RESULTS
The G70C4-G virus showed resistance to zanamivir in
enzyme inhibition assays, but not to 4-amino-Neu5Ac2en.
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However, G70C4-G was partially cross-resistant to 4-
amino-Neu5Ac2en in a plaque reduction assay, with resis-
tance to zanamivir being greater than that to 4-amino-
Neu5Ac2en (Blick et al., 1995). We have previously shown
variants with HA mutations to be equally cross-resistant to
zanamivir and 4-amino-Neu5Ac2en in cell culture (Mc-
Kimm-Breschkin et al., 1996a). These observations caused
us to reexamine the HA sequence, and a single mutation,
Ser 186 to Phe, was in fact detected.
Examination of passage history
Early passages from the generation of the G70C4-G
virus were also examined to elucidate the evolutionary
dynamics involved in the generation of the double mu-
tant. Each passage was amplified and the drug sensitiv-
ity was determined in a plaque reduction assay, with
mixed populations separated by plaque purification. A
variant with a relatively small change in drug sensitivity,
P1-1, arose at passage 1. Passage 3 consisted of a major
population of P1-1 and two highly resistant minor popu-
lations, each ,10% of the overall population, P3-1 and
P3-2. These two variants were not present in passage 4.
Passage 5 was a mixed population of P1-1 and G70C4-G.
Only G70C4-G was present by passage 6.
Sequencing of the HA genes
The HA of each variant was sequenced. All the vari-
ants, including G70C4-G, previously reported not to have
an HA mutation (Blick et al., 1995), had a Ser 186 to Phe
mutation (H3 numbering). P3-1 and P3-2 each had an
additional mutation; P3-1 had a Ser 165 to Asn mutation
and P3-2 had a Lys 222 to Thr mutation.
Generation of virus with only the NA mutation
The G70C4-G mutant was reassorted with its NWS/
G70C parent virus to generate a virus with the NA mu-
tation, but with a wild-type HA and the same background
genes. Slow elution from chicken erythrocytes was used
to select virus with a wild-type HA. Resistant virus was
distinguished from wild-type NWS/G70C on the basis of
resistance to zanamivir in a plaque inhibition assay.
Selection of the mutant, G70C4-G/NA, with the Glu 119 to
Gly NA mutation, but a wild-type HA, was confirmed by
NA inhibition assay and sequencing of the HA and NA.
This genotype is identical to that described by Staschke
et al. (1995). The plaque size of G70C4-G/NA was smaller
than the NWS/G70C plaque size.
Sensitivity of virus in plaque assay
Sensitivity to zanamivir and 4-amino-Neu5Ac2en was
determined by a plaque inhibition assay (results for
zanamivir shown in Fig. 1). While the G70C4-G double
mutant was 100-fold less sensitive to zanamivir (EC50 5
0.3 mg/ml, based on the concentration of drug required to
give a 50% in plaque size) than the wild type (EC50 5
0.003 mg/ml), P1-1 (HA mutant) and G70C4-G/NA (NA
mutant) were each only 10-fold less sensitive to zanami-
vir (EC50 5 0.03 mg/ml). The two mutations therefore
acted in a synergistic way to decrease drug sensitivity.
G70C4-G and P1-1 were 10-fold less sensitive to 4-ami-
no-Neu5Ac2en (EC50 5 3 mg/ml) than wild-type NWS/
G70C (EC50 5 0.3 mg/ml), but G70C4-G/NA was as sen-
sitive as the wild-type.
Both P3-1 and P3-2 were $1000-fold less sensitive to
zanamivir than NWS/G70C and were equally cross-resis-
tant to 4-amino-Neu5Ac2en. Both exhibited drug depen-
dence, having fewer plaques in the absence of inhibitor.
In addition, P3-1 also had small, diffuse plaques in the
absence of inhibitor.
Effect of exogenous NA
The NA mutation Glu 119 to Gly does not affect specific
activity (Blick et al., 1995), but does reduce NA stability
(McKimm-Breschkin et al., 1996b). To determine whether
the small plaque size of G70C4-G/NA was caused by a
deficiency of NA activity in vitro, exogenous NA was
added to the agar overlay in a plaque assay (Fig. 2). With
exogenous NA the plaque size of the G70C4-G/NA virus
increased to that of wild-type virus.
Kinetics of replication
To ascertain if there were other effects of the in vitro
NA deficiency, the kinetics of replication of G70C4-G/NA
was followed over 48 h and compared to that of wild-type
virus. Results showed that the replication of G70C4-
G/NA was not adversely affected.
Stability of the resistance phenotype
P3-2, P1-1, and G70C4-G/NA did not revert after pas-
saging in the absence of drug, as determined by drug
sensitivity in a plaque reduction assay and NA inhibition
assay for G70C4-G/NA. However, after 10 limiting dilution
passages in the absence of drug, P3-1 was now only
10-fold less sensitive to zanamivir than wild-type virus.
Sequencing revealed reversion to wild-type sequence at
residue 165 with maintenance of the Ser 186 to Phe
mutation.
Kinetics of adsorption
We have previously shown that virus may overcome
drug inhibition by HA mutations which decrease affinity,
allowing progeny virions to elute from cells with a re-
duced requirement for NA activity (McKimm-Breschkin et
al., 1996a; Sahasrabudhe et al., 1996). To determine if
these HA variants had a reduced efficiency of adsorption
compared to the wild-type virus, the kinetics of adsorp-
tion and penetration were studied. The efficiencies of
adsorption of G70C4-G and P1-1 were no different to that
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of the wild-type. The adsorption efficiencies of P3-1 and
P3-2 were reduced to 10–15% of that of the wild-type
virus.
Thermal stability of HA
We have previously shown mutations in the HA can
result in thermolability (McKimm-Breschkin et al., 1996a).
For each virus the thermal stability of the mutant HA was
assessed by incubating virus at elevated temperatures
for 1 h. Binding to fetuin was compared to a control
incubated at 4°C. None of the mutations lead to a
marked decrease in the thermal stability of the HA.
Infectivity and drug sensitivity in the mouse model
To determine whether the mutations had an effect in
vivo on virus replication or drug sensitivity, infectivity and
sensitivity to zanamivir were determined in the mouse
model (Fig. 3). In the absence of drug, NWS/G70C and
G70C4-G grew to comparable titers in animals infected
with the same inoculum, indicating that the in vivo infec-
tivity of G70C4-G was not affected. In drug treated mice
a reduction in mean virus lung titers was seen at both 1
mg/kg/dose (P 5 0.03) and 10 mg/kg/dose (P 5 0.02)
zanamivir for NWS/G70C. Mean virus lung titers for
G70C4-G were only reduced at the highest drug concen-
tration (P 5 0.004). G70C4-G was less sensitive to inhib-
FIG. 1. Plaque inhibition assay of NWS/G70C, the double mutant G70C4-G, and the single HA (P1-1) or NA (G70C4-G/NA) variants. Concentrations
of zanamivir are in mg/ml.
FIG. 2. Effect of exogenous NA on plaque size on NA only mutant and
wild-type viruses. One of each pair of plates was supplemented with 10
mU/ml of NA from Clostridium perfringens.
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itor than NWS/G70C at both 1 mg/kg/dose (P 5 0.04) and
10 mg/kg/dose (P 5 0.02). Overall G70C4-G was 10-fold
less sensitive to zanamivir than NWS/G70C.
Drug sensitivity in the ferret model
As influenza virus infection in ferrets more closely
resembles the clinical situation in humans, the drug
sensitivity of the G70C4-G mutant was determined in the
ferret model (Fig. 4). All three doses of zanamivir reduced
nasal virus titers over the course of infection, though to
differing degrees. There was no detectable difference
between the responses of ferrets infected with either
NWS/G70C or G70C4-G to any drug dose. All sham-
treated control animals, infected with either NWS/G70C
or G70C4-G, had a pyrexic response within the period
48–96 h postinfection. In contrast, the temperature re-
sponses of zanamivir-treated ferrets were completely
suppressed at doses of 5, 0.5, or 0.05 mg/kg in all ferrets
infected with either NWS/G70C or G70C4-G.
DISCUSSION
We have previously described a drug-resistant variant,
G70C4-G, with the active site mutation Glu 119 to Gly,
generated by passaging virus in the presence of zana-
mivir (Blick et al., 1995). While it was only resistant to
zanamivir in an enzyme inhibition assay, it also showed
some resistance to 4-amino-Neu5Ac2en in a plaque in-
hibition assay. This variant was subsequently found to
also harbor an HA mutation in the receptor binding site,
Ser 186 to Phe. To determine the contribution of each
mutation to resistance we separated the two mutations
by reassorting. These viruses, with a single mutation,
were used to measure the cooperative effects of muta-
tions in both the NA and the HA.
While the NA mutation Glu 119 to Gly and the HA
mutation Ser 186 to Phe each conferred low level resis-
tance to zanamivir, they interacted synergistically to give
higher in vitro resistance in the G70C4-G variant with
both mutations. Synergistic resistance to antiviral com-
pounds has previously been described for herpes sim-
plex virus (HSV) (Darby et al., 1984) and human immuno-
deficiency virus (HIV) (Lacey and Larder, 1994). In acy-
clovir-resistant HSV, mutations in the thymidine kinase
and the DNA polymerase behave synergistically to give
high-level resistance. Two HIV reverse transcriptase mu-
tations have been found to interact synergistically in
regard to resistance to zidovudine. More common are
synergistic resistance mechanisms to antibiotics in
gram-negative bacteria (reviewed in Stratton and Tausk,
1987; Hancock, 1997) and yeast (Howell et al., 1974;
Rowlands and Turner, 1977; Subik et al., 1977).
The NA only mutant showed no resistance to 4-amino-
Neu5Ac2en in a plaque inhibition assay, which corre-
FIG. 4. Zanamivir sensitivity in the ferret model. Ferrets were chal-
lenged i.n. with 2.5 3 105 PFU of either the NWS/G70C virus or
G70C4-G virus. Animals were dosed with distilled water or zanamivir
twice daily from the day before infection to day 5 after infection. Viral
titers were determined by TCID50 from nasal wash samples taken up to
9 days after infection.
FIG. 3. Infectivity and zanamivir sensitivity in the mouse model. Mice
were infected i.n. with 105 PFU of either the NWS/G70C virus or
G70C4-G virus. Animals were dosed with PBS or zanamivir at 220 and
24 h prior to infection and at 4, 20, 28, and 44 h postinfection. Four to
five mice were used per group. Lungs were harvested at 48 h postin-
fection. Lung virus titers were determined by TCID50. Data were col-
lated from three separate experiments.
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lated with complete sensitivity to the compound in an NA
inhibition assay (Blick et al., 1995). The 10-fold resistance
of G70C4-G to 4-amino-Neu5Ac2en seen previously
(Blick et al., 1995) correlates with the resistance of the
HA only mutant P1-1 to the inhibitor and thus derives
solely from the HA mutation.
We examined plaque progeny from early passages of
G70C4-G to determine when these individual mutations
arose. The HA mutation of this double mutant had arisen
by the first passage. However from a subsequent pas-
sage two other new HA variants, P3-1 and P3-2, were
isolated, which had each acquired a different additional
mutation in the HA, Ser 165 to Asn and Lys 222 to Thr,
respectively. These additional mutations increased resis-
tance significantly, but interestingly both caused drug
dependence. Neither of these variants were isolated
from the subsequent passage, whereas the single Ser
186 to Phe mutation was maintained and the NA muta-
tion was subsequently acquired at passage five.
The decreased drug sensitivity and drug dependence
of P3-1 and P3-2 were similar to those of two resistant
variants with HA mutations reported by McKimm-Bresch-
kin et al. (1996a). We have previously shown that the HA
and NA mutations in G70C4-G were stable when the
virus was passaged in the absence of drug (Blick et al.,
1995). Here we have found that this is also true for
viruses with either one of these two mutations.
The two HA mutations in P3-2 were also stable when
passaged in the absence of drug. In the most drug-
dependent variant, P3-1, the weak Ser 186 to Phe was
stable, but there was enough selective pressure to force
the reversion of residue 165 to wild-type sequence, re-
moving the potential glycosylation site in the mutant,
correlating with loss of drug-dependence and a de-
crease in drug-resistance.
An NWS/G70C HA variant derived from passaging in
another NA inhibitor, a 6-carboxamide derivative of zana-
mivir, has been generated, having a single Ser 165 to Asn
mutation. This mutant had 30-fold resistance to NA in-
hibitors and was not drug dependent (McKimm-Bresch-
kin et al., 1998). As the Ser 186 to Phe mutant P1-1 was
only 10-fold resistant to zanamivir, while the double HA
mutant P3-1 was $1000-fold resistant, the two HA mu-
tations must act synergistically to increase resistance.
Previously three resistant variants with mutations in
their HA (McKimm-Breschkin et al., 1996a) have been
shown to have reduced efficiencies of adsorption (Sa-
hasrabudhe et al., 1996). Based on the small change in
resistance due to the Ser 186 to Phe mutation, this
mutation is unlikely to have a large impact on the affinity
of the HA for its receptor. The efficiencies of adsorption
of G70C4-G and P1-1 were no different from that of the
wild-type. The adsorption efficiencies of the more resis-
tant P3-1 and P3-2 were significantly reduced compared
to the wild-type virus, correlating with a significant de-
crease in the affinity of the HA for its receptor. For these
drug-dependent variants, as the adsorption and penetra-
tion steps were not as efficient as for the wild-type virus,
the virus NA may cleave receptors on cell surfaces
before virus can infect. Presence of drug prevents cleav-
age of cell surface receptors, allowing virus to adsorb to
and penetrate cells.
Some HA mutations have previously been shown to
lead to thermal instability (McKimm-Breschkin et al.,
1996a). These current mutations affected the affinity but
not the stability of the HA trimer.
Here we report mutations at three residues in the HA
(Table 1). In terms of the structural implications of these
HA mutations, Ser 186 is not conserved across HA sub-
types, but it is in close proximity to the receptor binding
pocket. A change at this residue to Ile has been impli-
cated in egg adaptation (Meyer et al., 1993) and mutation
at residue 186 has been postulated as an important
switch in the specificity of the receptor binding site from
an avian receptor to a human receptor (Matrosovich et
al., 1997). Therefore it is feasible that the Ser 186 to Phe
mutation has a small impact on receptor binding, corre-
lating with its biological properties. In addition to Ser 186
to Phe, the P3-1 mutant had a Lys 222 to Thr mutation.
Residue Lys 222 is flanked by a pair of known conserved
TABLE 1
Sequence Changes in the HA and NA Proteinsa and in Vitro Zanamivir Sensitivityb
Virus
NA amino acid
at position 119
HA amino acid at position:
EC50
(zanamivir mg/ml)165 186 222
NWS/G70C parent E S S K 0.003
P1-1 E S F K 0.03
P3-1 E N F K $3
P3-2 E S F T $3
G70C4-G G S F K 0.3
G70C4-G/NA G S S K 0.03
a Amino acid numbering is based on the H3 HA and the N2 NA. Sequence changes are shown in boldface.
b EC50 based on the concentration of zanamivir required to give a 50% reduction in plaque size.
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residues (220–221) and a stretch of residues 224–229
described as the left edge of the receptor binding pocket
(Nobusawa et al., 1991). In H3, residue Trp 222 has been
shown to be directly involved in the binding of 2,6-
sialyllactose (Eisen et al., 1997). The biological proper-
ties of this mutant indicate a significant additional effect
of this mutation which would correlate with its close
association with other residues involved in receptor
binding. The P3-2 virus with the additional Ser 165 to Asn
mutation introduces a potential glycosylation site on the
globular head of the HA. Residue 163 is frequently a
glycosylation site in human H1, as is residue 165 in H3.
Carbohydrate from this glycoslyation site could extend
across the receptor binding site of adjacent monomers
of the HA homotrimer. Increased glycosylation of the
globular head of the HA has been shown to decrease
binding affinity (Matrosovich et al., 1997), which would
correlate with our findings.
The NA mutation Glu 119 to Gly caused a small pla-
quing phenotype, which was rescued by NA supplemen-
tation, indicating that it was due to an NA deficiency. This
did not affect the kinetics of virus replication, which is in
agreement with Gubareva et al. (1997), who also found
that mutations at Glu 119 did not affect the ability of virus
to replicate in vitro, but differs from the results of Stas-
chke et al. (1995), who found that an NA-only mutant, with
the same NA mutation, displayed delayed kinetics. Since
the NA-specific activity of the Glu 119 to Gly mutant is no
different from that of wild-type (Blick et al., 1995), it is
most likely that the instability of the mutant NA (McKimm-
Breschkin et al., 1996b) is the cause of the small plaqu-
ing phenotype of this mutant. The normal plaque size of
the G70C4-G variant is probably due to rescue of the NA
deficiency by the HA mutation, which reduces the de-
pendence on the NA.
The infectivity of the double mutant, G70C4-G, was not
affected in mice or ferrets, in contrast to a Glu 119 to Ala
mutant which previously demonstrated slightly lower in-
fectivity in mice (Gubareva et al., 1997). There was only a
10-fold decrease in sensitivity to zanamivir seen in the
mouse model with G70C4-G, while there was a 100-fold
resistance seen in cell culture. Furthermore, in the ferret
model, which more closely resembles the natural upper
respiratory tract infection of humans by influenza, there
was no detectable reduction in sensitivity to zanamivir
and pyrexia was still prevented. The different sites of
infection in the two models may have contributed to the
different results. Only one of these two mutations may
lead to resistance in vivo. Another group has reported an
HA mutation that caused high in vitro resistance, but no
change in zanamivir sensitivity in the mouse model
(Penn et al., 1996). It is possible that this particular HA
mutation may not contribute to resistance in vivo.
We have therefore demonstrated for the first time that
either combinations of NA and HA mutations or two HA
mutations can act synergistically to increase resistance
to NA inhibitors. The role of HA and NA mutations in vivo
is still unclear.
MATERIALS AND METHODS
Virus
The NWS/G70C virus (H1N9) was originally obtained
from Dr. Robert Webster (St. Jude Children’s Medical
Research Center, Memphis, TN). It contains the NA gene
of the A/tern/Australia/G70C/75 (N9) virus and the re-
mainder of the genes are derived from the NWS virus.
Cells and media
MDCK cells were grown in Dulbecco’s modified Ea-
gle’s medium/Ham’s F12 (DMEM), supplemented with
10% fetal bovine serum, penicillin/streptomycin (Trace
Biosciences, Australia), glutamine (Sigma Chemical Co.,
St. Louis, MO), and fungizone (Squibb, Australia). For
virus culture cells were maintained in maintenance me-
dium (MM), consisting of minimal Eagle’s medium (Life
Technologies, U.S.A.) and Liebovitz L15 (Trace Bio-
sciences, Australia), 1:1, without serum, supplemented
with glutamine, penicillin/streptomycin, and fungizone.
Inhibitors
Zanamivir and 4-amino-Neu5Ac2en were synthesized
by Glaxo Wellcome Research and Development Ltd.
(Stevenage, UK).
Examination of passage history
To determine when mutations contributing to resis-
tance arose, the original passages 1 to 6 of the G70C4-G
virus were amplified and were tested for drug sensitivity
in a plaque reduction assay. For phenotypically mixed
populations individual mutants were isolated by plaque
purification.
Generation of virus with only the NA mutation
The G70C4-G mutant was reassorted with the NWS/
G70C wild-type by coinfection at high multiplicity of in-
fection (m.o.i.) into MDCK cells. Reassorted viruses were
grown overnight in 1 mg/ml of zanamivir in MM. Progeny
were plaqued in DMEM only or in DMEM containing
log10 dilutions of zanamivir ranging from 0.0003 to 3.0
mg/ml. Plaques grown in DMEM only and each drug
concentration were picked and amplified. Amplified
plaques were agglutinated with chicken erythrocytes at
4°C for 1 h and were then incubated at 37°C for 3 h to
allow elution of the virus. Virus with the wild-type HA
elute much more slowly than the mutant virus (McKimm-
Breschkin et al., 1996a). On this basis, amplified slow
eluting progeny with a putative wild-type HA were se-
lected. To select progeny which retained the NA muta-
tion, relative drug sensitivity was assayed in a plaque
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inhibition assay. Conservation of the NA mutation was
confirmed by an NA enzyme inhibition assay followed by
sequencing of the NA gene. Loss of the HA mutation was
confirmed by sequencing.
Sensitivity of virus in plaque assay
Approximately 100 PFU of virus was inoculated onto
MDCK cells in 55-mm petri dishes. Virus was adsorbed
for 1 h before cells were overlaid with agarose contain-
ing log10 dilutions of zanamivir ranging from 0.0003 to 3
mg/ml or 4-amino-Neu5Ac2en ranging from 0.01 to 100
mg/ml. Cells were fixed after 4 days with 1% Formalin in
saline, agarose was removed, and plaques were stained
with 0.05% neutral red.
Sequencing of the NA and HA genes
Influenza virus RNA was extracted directly from in-
fected tissue culture supernatants and was digested
with proteinase K in 0.5% SDS for 10 min. RNA was
extracted twice using phenol chloroform and was pre-
cipitated with ethanol. Full-length NA and HA cDNA were
prepared from the virion RNA using AMV reverse tran-
scriptase (Progema, U.S.A.). For each gene three seg-
ments were amplified by PCR for direct PCR sequencing.
Sequences were determined using the PRISM Ready
Reaction Dyedeoxy Terminator Cycle Sequencing Kit
(Applied Biosystems, U.S.A.). Sequence analysis was
done using the Macintosh-based DNA analysis software
GeneJockey II (Biosoft Corp., UK).
NA enzyme inhibition assays
NA enzyme activity was determined using a modifica-
tion of the method of Potier et al. (1979). Briefly, 25 ml of
virus and 25 ml of dilutions of zanamivir were preincu-
bated for 30 min at room temperature before the addition
of 50 ml of 0.2 mM methylumbelliferone N-acetylneura-
minic acid (kindly provided by Keith Watson, Biota Hold-
ings Chemistry Laboratory) in a buffer containing 10 mM
CaCl2 and 100 mM sodium acetate. After 1 h reactions
were stopped with 200 mM Na2CO3. Fluorescence was
quantitated in a Perkin–Elmer fluorimeter (Model LS50B),
using an excitation wavelength of 365 nm with a slit
width of 2.5, and an emission wavelength of 450 nm with
a slit width of 20. Virus for enzyme assays was grown in
the absence of drug. NA activity was determined over a
range of virus dilutions to determine virus titers for which
the enzyme activity was linear.
Effect of exogenous NA
To determine whether NA activity was a limiting factor
in the small plaque size of the variant with only the NA
mutation (G70C4-G/NA), exogenous NA from Clostridium
perfringens (Sigma Chemical Co.) was added at 10
mU/ml to the agar overlay in a plaque assay with G70C4-
G/NA and NWS/G70C. Plaque sizes with and without
exogenous NA were compared.
Kinetics of replication
NWS/G70C and G70C4-G/NA were inoculated at an
m.o.i. of 0.1 onto MDCK cells in 24-well cluster dishes.
After 1 h at 37°C the inoculum was removed and was
replaced with 1 ml of MM. Quadruplicate samples were
collected at 8-h intervals and these were titrated by
TCID50. Cells were fixed and stained after 4 days and
were scored for CPE.
Stability of the resistance phenotype
Resistant viruses were serially passaged by limit dilu-
tion, in the absence of drug, for 10 passages. At each
passage serial log10 dilutions of virus were inoculated
onto MDCK cells in a 24-well cluster dish. Three rows
were grown in the absence of drug, and one row was
grown in the presence of drug. Virus growth was ob-
served visually and quantitated by a slot blot immunoas-
say. Relative drug sensitivity could then be assessed.
Virus showing growth from the lowest dilution in the
absence of drug was used for each subsequent pas-
sage. After 10 passages viruses were tested for resis-
tance in plaque assays and, for G70C4-G/NA, an en-
zyme inhibition assay. Reversion was confirmed by
sequencing.
Kinetics of adsorption
Adsorption efficiency was determined by comparing
the number of cells infected after different adsorption
periods. MDCK cells were grown on quarter microscope
slides. Confluent cells were washed with cold PBS and
then were infected with an equivalent m.o.i. of NWS/
G70C parent virus and each of the variants, G70C4-G,
P1-1, P3-1, and P3-2, in a volume of 100 ml. To synchro-
nize infection adsorption was carried out at 0°C for 20,
40, and 60 min, after which the inoculum was removed,
100 ml of MM was added, and cells were incubated at
37°C for 6 h. The control in each case was adsorption at
0°C for 1 h, followed by 37°C for 1 h, after which the
inoculum was removed, MM was added and cells were
incubated a further 5 h at 37°C. After incubation at 37°C
slides were washed with PBS and were fixed in chilled
acetone. Cells were incubated with an anti-NP monoclo-
nal antibody (ATCC HB65), for 1 h at room temperature,
washed in PBS, stained with FITC conjugate (Silenus,
Australia) for 1 h, and were again rinsed in PBS, followed
by a water rinse. Slides were air dried and were ob-
served under an Olympus BH2 fluorescence microscope.
Thermal stability of HA
Virus stocks were diluted in MM to give equivalent
amounts of HA as determined by titrations on fetuin
101ZANAMIVIR-RESISTANT MUTATIONS
(Sigma Chemical Co.)-coated ELISA plates, with detec-
tion by E1.2, a monoclonal antibody to the HA (kindly
provided by Margot Anders, Microbiology Department,
Melbourne University). Diluted virus was incubated in
triplicate at 0°, 45°, 50°, 55°, and 60°C for 1 h. Remain-
ing native HA was measured by ELISA and was ex-
pressed as a percentage of the 0°C control.
Infectivity and drug sensitivity in the mouse model
Six-week-old female C57BL6 3 C57BL10 mice (W.E.H.I.,
Melbourne) were infected i.n. with 105 PFU of either the
NWS/G70C virus or G70C4-G in 50 ml of PBS. Animals
were treated i.n. with PBS or were treated with zanamivir
at 0.1, 1, or 10 mg/kg/dose in 50 ml PBS. Animals were
dosed with drug at 220 and 24 h prior to infection and
postinfection at 4, 20, 28, and 44 h. Four to five mice were
used per group. Animals were sacrificed at 48 h postin-
fection and lungs were harvested. Lungs were washed
with PBS and were homogenized in 1.5 ml PBS. Homog-
enates were sonicated and were clarified at 15K for 2
min. Lung virus titers were determined by TCID50. Cells
were fixed and stained after 4 days and were scored for
CPE. Data were collated from three separate experi-
ments. Relative infectivity was determined by comparing
the growth of each virus in PBS-treated animals. For
statistical analysis, t tests were performed using Graph-
Pad Prism (GraphPad, U.S.A.).
Drug sensitivity in the ferret model
Groups of four animals were dosed with either distilled
water or zanamivir at 5, 0.5, or 0.05 mg/kg/dose, twice
daily (8 h apart) from the day before infection to day 5
after infection. On the day of infection the first treatment
dose was given 2 h before infection. To help with intra-
nasal dosing ferrets were sedated with gaseous isoflu-
orane (Abbott Lab., UK). Ferrets were challenged by
intranasal instillation of 0.25 ml of diluted virus contain-
ing 106 PFU/ml of either NWS/G70C or G70C4-G. Tem-
perature responses were measured by telemetry. Bat-
tery-operated transmitters (Dataquest, Data Sciences,
U.S.A.) were implanted into the peritoneal cavity 7 days
before infection. Telemetric data were collected by ded-
icated receivers (RLA 2000, Data Sciences). Temperature
profiles were measured prior to and during the influenza
virus infectious period. Infection was monitored by taking
nasal wash samples on days 1–9 after infection, and
virus titers were determined as tissue culture infectivity
(in MDCK cells) by limiting dilution.
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